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Mutations in FOXP2 cause developmental verbal dyspraxia (DVD), but only a few cases have been described. We char-
acterize 13 patients with DVD—5 with hemizygous paternal deletions spanning the FOXP2 gene, 1 with a translocation
interrupting FOXP2, and the remaining 7 with maternal uniparental disomy of chromosome 7 (UPD7), who were also
given a diagnosis of Silver-Russell Syndrome (SRS). Of these individuals with DVD, all 12 for whom parental DNA was
available showed absence of a paternal copy of FOXP2. Five other individuals with deletions of paternally inherited
FOXP2 but with incomplete clinical information or phenotypes too complex to properly assess are also described. Four
of the patients with DVD also meet criteria for autism spectrum disorder. Individuals with paternal UPD7 or with partial
maternal UPD7 or deletion starting downstream of FOXP2 do not have DVD. Using quantitative real-time polymerase
chain reaction, we show the maternally inherited FOXP2 to be comparatively underexpressed. Our results indicate that
absence of paternal FOXP2 is the cause of DVD in patients with SRS with maternal UPD7. The data also point to a role
for differential parent-of-origin expression of FOXP2 in human speech development.
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Forkhead-box P2 (FOXP2) was the ﬁrst gene discovered to
be involved in speech and language disorder, through ge-
netic mapping and mutational analysis in a three-gener-
ation pedigree (referred to as the “KE” family) with an
autosomal dominant form of the condition.1–3 Character-
ization of a translocation breakpoint in a patient (called
“CS”) with a similar clinical presentation added further
support.2 The KE phenotype is described as severe devel-
opmental verbal apraxia with impairment in both ex-
pressive and receptive language skills,3 categorized as de-
velopmental verbal dyspraxia (DVD [MIM 602081]). Dis-
ruption of both copies of Foxp2 in mice causes severe mo-
tor impairment, premature death, and absence of ultra-
sonic vocalizations normally elicited when pups are sep-
arated from their mothers.4 In the heterozygous-knockout
mice, there is modest developmental delay but a signiﬁ-
cant alteration in ultrasonic vocalizations.
The FOXP2 protein is an evolutionarily conserved tran-
scriptional repressor containing a zinc-ﬁngermotif, a fork-
head DNA-binding domain, and a polyglutamine tract.5
There are several isoforms of the gene, with the longest
characterized transcript encompassing 25 exons spanning
1600 kb of DNA (ﬁg. 1)5; the gene is expressed in a wide
range of tissues throughout development. On the basis of
structural and functional studies in the KE family, FOXP2
has been suggested to be involved in the development of
brain regions affecting motor control and neural struc-
tures that mediate speech and language.6 The KE family
carries a heterozygous point mutation in exon 14 (amino
acid 553, resulting in an arginine-to-histidine change) of
the FOXP2 consensus. Transmission of mutated FOXP2 is
maternal, except in one case of paternal transmission.3
The chromosome 7 translocation breakpoint (parental or-
igin not described) in CS occurs between exons 3b and
4, disrupting all known isoforms of FOXP2. Recently, a
screen for FOXP2 mutations in 49 probands with verbal
dyspraxia as their primary phenotype detected a mater-
nally inherited nonsense mutation yielding a truncated
protein in one family, as well as two putative missense
mutations in two other patients.7 These ﬁndings suggest
that FOXP2mutations are a relatively rare cause for speech
and language impairment.
The distinctive clinical presentation of the KE family8
has served as a reference for us to identify patients with
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Figure 1. A, Summary of the chromosomal aberrations in patients with and without DVD. Patient numbers correspond to descriptions
in table 1. The location of FOXP2 is denoted by the dotted line. Two known clusters of imprinted genes on 7q are shown above the
chromosome. SGCE, PEG10, MEST, COPG2IT1, and MESTIT1 are paternally expressed, and PPPIR9A and CPA4 are maternally expressed. A
new paternally imprinted gene, KLF14, is also now known to reside at 7q32 (L. Parker-Katiraee, personal communication). B, FOXP2
locus at 7q31.2. A consensus transcript encompassing all known exons of the gene is presented. Coding exons are shown in black. The
translocation breakpoint (transl. bkpt.) for patient 6 and the proximal deletion breakpoint (prox. del. bkpt.) for patient 4 map between
exons s1 and s2. The KE mutation and the CS translocation breakpoint,2 as well as a nonsense mutation in exon 7 that segregates with
the DVD phenotype,7 are also shown. Known functional motifs are indicated below the exons coding for each. Mapping reagents,
including BAC clones, long-PCR FISH probes, and microsatellite markers, are shown. Markers HSC274–HSC279 are in GenBank, under
accession numbers BV123532, BV123533, BV123528, BV123529, BV123530, and BV123531, respectively. Additional probes and mapping
reagents can be found at the Chromosome 7 Annotation Project Web site and will be distributed on request.
a similar phenotype. In addition, we have been collecting
patients with chromosomal anomalies affecting chro-
mosome 7,9 with a speciﬁc focus on patients with an af-
fected FOXP2 locus. Thus, patients have been ascertained
both via genotype and via phenotype. A speciﬁc subgroup
of patients displaying DVD (in addition to other pheno-
typic characteristics) includes patients with maternal uni-
parental disomy (UPD) of chromosome 7 (matUPD7). We
hypothesized that this can be attributed to FOXP2 and
that there may be a parent-of-origin effect involved in
FOXP2 regulation. The aim of this article is to describe the
genetic and phenotypic similarities among patients ex-
hibiting DVD, with FOXP2 as a main focus.
We characterized 22 samples in this study. In this article,
we describe 13 individuals with DVD who can be divided
into groups on the basis of their genetic characteristics
(table 1)—namely, group A, consisting of 5 individuals
with 7q31 deletions of FOXP2 on the paternally inherited
chromosome; group B, consisting of 1 individual with a
7q31 translocation interrupting FOXP2; and group C, con-
sisting of 7 patients with matUPD7. Table 1 also describes
nine individuals without DVD. Group D includes two pa-
tients, one with with partial matUPD7 and one with a de-
letion, with rearrangements starting downstreamofFOXP2;
group E includes two patients with paternal UPD7
(patUPD7); and group F has ﬁve patients with FOXP2 de-
letions (on the paternally derived chromosome) and a
more complex global developmental delay, including
speech and language disorder.
The patients with matUPD7 have also received diag-
noses of Silver-Russell Syndrome (SRS [MIM 180860]), a
condition characterized by intrauterine growth retarda-
Table 1. Summary of 22 Individuals with or without DVD
Group and Patient
(Alias and Reference)a
Karyotype (Deletion Size
or Parental Source)b
Presence of Traitc
Phenotyped
Late
Talking
Oromotor/
Verbal
Dyspraxia
Articulation
Disorder
Receptive
Language
Impairment
Expressive
Language
Impairment
Speech
Therapy
Below-Average
Nonverbal/
Performance
IQ
Gross- and/
or Fine-
Motor Delays
Reference:
KE2 Point mutation       /  DVD
CS2 t(5;7)(q22q31.2)      NR   DVD
A:
1 (13772) 46,XX,del(7)(q31.1q31.3)pat (15 Mb)         DVD and DD
2 (27162) 46,XX,del(7)(q31.2q32)pat (13 Mb)         DVD
3 (24784) 46,XY,del(7)(q31.1q31.3)pat (11 Mb)         DVD and ASD
4 (13583)11 46,XX,del(7)(q31.2q32.3)pat (15 Mb)         DVD and ASD-like
5 (33466) 46,XX,del(7)(q22q31.3)pat (15 Mb)        NR DVD and DD
B:
6 (28577) 46,XX,t(3;7)(q23q31.2)       NR  DVD
C:
712 46,XY,matUPD7 (iso)         DVD and SRS
812 46,XY,matUPD7 (iso/hetero)  NR     NR NR DVD and SRS
912 46,XX,matUPD7 (iso/hetero)       NR  DVD and SRS
1012 46,XX,matUPD7 (iso/hetero)    NR   NR  DVD and SRS
1113 46,XX,matUPD7 (iso)  NR  NR NR    DVD and SRS
12 (LGL12989) 46,XX,matUPD7 (iso)  NR     NR  DVD and SRS
13 (27297) 46,XY,matUPD7 (iso)         DVD, SRS, and ASD
De:
14 (C70001-3) 46,XY,del(7)(q31.2q32.3)pat (15 Mb)         DD
1514 46,XX,matUPD7q31-qter (iso)         SRS
E:
1615 46,XX,patUPD7 (iso)         CLD
17 (18406) 46,XY,patUPD7 (unknown)         DD and CF
Ff:
18 (23145) 46,XY,del(7)(q31.2q32)pat (26 Mb) NR NR NR NR NR NR   DD, no speech, and ASD
19 (6635) 46,XY,del(7)(q22q31.33)pat (22 Mb) NR NR NR NR NR NR NR NR NR
20 (10203) 46,XX,del(7)(q31.2q32.2)pat (14 Mb)   NR NR NR NR   DD
21 (11912) 46,XX,del(7)(q31.1q33)pat (30 Mb) NR NR NR NR NR NR   DD and no speech
22 (31065) 46,XY,del(7)(q31.2q32)pat (21 Mb) NR NR NR NR NR NR   DD and no speech
a Literature and database searches revealed another 16 patients (not shown) whose karyotypes suggest deletion of FOXP2, but no molecular or parent-of-origin data are available. Moreover, most
of these patients were described as infants, and a speciﬁc language phenotype was therefore not included. Additional details for these samples and for those described in the table can be found at
the Chromosome 7 Annotation Project Web site. We note that we do not see any neutral copy-number variants in the FOXP2 region (see the Database of Genomic Variants10).
b For patients with UPD, the source of parental chromosomes—isodisomic (iso), heterodisomic (hetero), or both—is shown, if known.
c Plus () indicates positive scoring on this trait, and minus () indicates negative scoring. NR p not recorded. IQ p intelligence quotient.
d The ﬁnal phenotype, as decided by multidisciplinary assessment, is shown. DD p developmental delay. CF p cystic ﬁbrosis. CLD p congenital chloride diarrhea. Speciﬁc phenotypic details for
any patients are available on request.
e Representative patients with chromosome 7 aberrations, FOXP2 intact, and no DVD.
f Patients with paternally inherited FOXP2 deletions but with incomplete clinical information or too complex a phenotype for the proper assessment of DVD.
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tion, postnatal short stature, and a characteristic, small
triangular face. Dysmorphic features such as ﬁfth-ﬁnger
clinodactyly and skeletal asymmetry are also common in
patients with SRS but are not required for diagnosis. Ap-
proximately 10% of patients with SRS have matUPD7.13,
16,17 Whereas DVD is not a frequent symptom in patients
with SRS in general, it is commonly found in the subgroup
of patients with matUPD7.12 PatUPD7 has no apparent
effect on growth and development, indicating that an im-
printed gene on chromosome 7 may be involved in caus-
ing SRS.12,18
All individuals described in groups A, B, and C in table
1 had normal hearing. One of us (J.O.C.) had previously
studied the prototypic KE family, which allowed direct
comparisons of clinical descriptions to be made. Blood
samples were collected and lymphoblast cell lines were
established from a subset of the patients and their parents.
The study was approved by the ethical review board of
each hospital involved in this study. All patients and their
families gave written consent. Karyotyping was performed
on blood from all patients and, for the parents of patients
with deletions, by analysis of G-banded metaphase chro-
mosomes from cultured peripheral blood lymphocytes
(table 1 and ﬁg. 1). All parental karyotypes were normal,
indicating that deletions were de novo. The site and/or
extent of the chromosomal rearrangement(s) or UPDs and
inheritance patterns were determined using a combina-
tion of genotyping, array comparative genomic hybridi-
zation, and FISH.
One patient (patient 6) carried a translocation inter-
rupting the FOXP2 gene. To our knowledge, only two pa-
tients with a translocation or inversion breakpoint within
FOXP2 have been described elsewhere.2,19 The transloca-
tion breakpoint in patient 6 is localized to the intron be-
tween the ﬁrst two 5′ UTR exons (s1 and s2) (ﬁg. 1) of the
longest known isoform of FOXP2 (not characterized in the
original mutation study). Parental samples were not avail-
able for analysis.
As summarized above, we observed that the remaining
12 individuals with conﬁrmed DVD (5 with deletions
and 7 with matUPD7) for whom inheritance could be
established failed to have a paternally inherited FOXP2
gene. In contrast, patient 14, with an interstitial 7q31.2-
q32.3 deletion starting just telomeric of FOXP2 (but
leaving it intact), and patient 15, with partial matUPD7
(matUPD7q31-qter) (ﬁg. 1)14 and both parental copies of
FOXP2, did not exhibit any characteristics of DVD. In
group E (patients 16 and 17), absence of maternally in-
herited alleles in patUPD7 also does not lead to DVD.
Patient 16, affected with recessive congenital chloride di-
arrhea,15 had normal psychomotor and speech develop-
ment without any articulation difﬁculties. Patient 17 (a
patient with cystic ﬁbrosis) had mild language delay, but
this was likely due to general developmental delay, and
he did not exhibit verbal dyspraxia. No data from either
our current study or the literature yet document a mater-
nal deletion of FOXP2; however, one maternally inherited
translocation interrupting FOXP2 has been described.19
These observations suggest a role for differential parental
regulation of FOXP2 expression and lead us to reconsider
possible mechanisms of FOXP2 activity in the patho-
physiology of DVD and in normal development.
Patients with an interstitial deletion encompassing
FOXP2 (patients 1–5) (table 1) as well as with the
t(3;7)(q23;q31.2) translocation interrupting FOXP2 (pa-
tient 6) all have a more severe form of DVD compared
with the KE family members. Data on the patients’ speech
disorders were collected from evaluations by a phoniatric
specialist, a speech-language pathologist, or a neuropsy-
chologist. The majority of these patients have some extent
of psychomotor delay and global cognitive impairment,
but the speech and language deﬁcits are much more se-
vere. All areas of speech and language development are
seriously affected; receptive language is less impaired than
expressive language, and articulation is the most compro-
mised. For example, at age 8 years, patient 3 had non-
verbal cognitive functioning at a 6-year age level, receptive
language at a 4.5-year level, expressive language at a 34-
mo level, and articulation at a 25-mo level. First words
were typically produced at age 3 (mean  SD 36  14
mo; ), whereas most children typically produce theirnp 6
ﬁrst word (other than “mama” or “dada”) by the end of
their 1st year. Two patients (3 and 4) started combining
words (which typically begins at ∼19 mo) at ages 4 and 6
years, respectively, with the remainder having failed to
attain this expressive language milestone. All patients
have greatly limited oral vocabulary size. Because of the
severe verbal dyspraxia, speech is restricted to the simplest
of sounds and is often unintelligible. In their early years,
these patients suffered from difﬁculties with chewing, gag-
ging, and swallowing, often to the extent that aspiration
occurred (table 1). Problems with coughing, throat clear-
ing, and sneezing are observed in most patients, and some
are unable to blow their noses. Oromotor problems in-
clude difﬁculties with lip protrusion, tongue elevationand
lateralization, and rapid alternating movements.
In addition to the six patients with DVD with deletion
or translocation rearrangements described above, we doc-
ument another ﬁve patients (group F) who all carry de
novo deletions of the paternally inherited chromosome
that includes the FOXP2 region (table 1 and ﬁg. 1). These
individuals could not be given formal diagnoses of DVD
since (i) we had limited clinical information about them
(e.g., patients 19 and 20) or (ii) they suffered from global
developmental delay (e.g., patients 18, 21, and 22) com-
plicating phenotypic assessment. The more complex phe-
notype in patients 18, 21, and 22 may be due to the larger
deletions (all 120 Mb in size) they harbor, compared with
the smaller deletions (all !15 Mb in size) observed in the
ﬁve individuals having conﬁrmed DVD (group A) (table
1). Notwithstanding, we do know that all ﬁve group F
patients have severe dyspraxia and language delay, with
three patients (18, 21, and 22) remaining nonverbal at
ages 10, 11, and 20, respectively.
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In the patients with FOXP2 deletion, there are addi-
tional phenotypic complexities, and, although these com-
plexities could be due to the size of the chromosomal
lesion (see ﬁg. 1 and table 1), no obvious features are con-
sistently observed. For example, patient 3, who has the
smallest deletion (11.3 Mb), meets the full criteria for au-
tism spectrum disorder (ASD [MIM 209850]), on the basis
of the Autism Diagnostic Observation Schedule (ADOS)
and the Autism Diagnostic Interview-Revised (ADI-R) ex-
ams. Patient 18 was also given a diagnosis of ASD on the
basis of similar criteria. Patient 4 (with a 15.4-Mbdeletion)
was initially given a diagnosis of ASD because she exhib-
ited repetitive behaviors, such as hand ﬂapping, and un-
usual sensory interests indicated by snifﬁng and squeez-
ing. On reexamination, however, it was determined that
she does not meet full ADOS or ADI-R criteria for ASD
because of her strong social communication, which in-
cluded spontaneous use of varied gestures to compensate
for her language difﬁculties.11 There is a history of Wil-
liams-Beuren syndrome (WBS [MIM 194050]) in her fam-
ily, and she carries the WBS-susceptibility inversion20; be-
cause of these complexities, we categorized her as “ASD-
like.” Patients 1 and 5, who have deletions encompassing
the region absent from patient 3, do not exhibit ASD.
Importantly, other than DVD, none of the patients with
the FOXP2 deletion exhibit any other features commonly
observed in patients with SRS.
The patients with matUPD7 and SRS (patients 7–13) all
have marked speech delay and difﬁculties in speech out-
put, especially articulation. It is noteworthy that SRS is
clinically and genetically heterogeneous, but mainly only
patients with complete matUPD7 (∼10% of patients with
SRS) exhibit DVD. The dyspraxia phenotype is very similar
to that in individuals with FOXP2 deletions but is some-
what milder. First words were usually spoken at 1.5–2.5
years (mean SD 24 5.9 mo; ). Whereas receptivenp 4
language skills range from mildly delayed to average, all
suffer from impairment in the expressive domain. Artic-
ulation difﬁculties with oromotor dyspraxia make the
speech unclear and difﬁcult to understand. This is com-
bined with a limited vocabulary and problems with word
ﬁnding. Although signiﬁcant improvement is made over
time with targeted speech therapy, the oldest patient (pa-
tient 7, age 24 years) is still slightly inarticulate and con-
tinues to have problems ﬁnding words. Similar to the pa-
tients with deletion of FOXP2, the patients withmatUPD7
suffered from difﬁculties with chewing, swallowing, and
feeding in the early years. Problems with laughing are ob-
served in most patients, and some have difﬁculty cough-
ing, sneezing, clearing their throats, and blowing their
noses. Although all aspects of oromotor functioning are
similar between patients with deletions and patients with
matUPD7 in the ﬁrst year of life, the phenotype in the
patients with matUPD7 is milder, and its progression fares
better. We note that patient 13 was ﬁrst referred to the
study on the basis of a DVD and ASD diagnosis; the SRS
phenotype was assessed only after genotyping revealed
matUPD7.
To assess how expression of FOXP2 was affected in the
different patient groups, we performed quantitative real-
time PCR (qPCR), on RNA obtained from lymphoblast
cell lines, for a subset of patients (ﬁg. 2). For the deletion
group, we included patients 1–4, 18, and 21. The PCR was
designed to amplify the forkhead-domain regionof FOXP2
(exons 13–14), and GAPDH was used as internal control.
Each sample was run in triplicate. The lowest expression
was found in the patients with matUPD7, followed by the
patients with deletions, the patient with the translocation,
the controls, and the patients with patUPD7. The differ-
ence in expression among the groups was signiﬁcant, as
assessed by one-way ANOVA ( ), and the post hocPp .0003
test showed signiﬁcant difference between patients with
matUPD7 and controls and between patients with dele-
tions and controls. There was no signiﬁcant difference be-
tween patients with matUPD7 and those with the dele-
tion. The patients with the translocation and patUPD7
were not included in the statistical analysis because of the
small number of samples available in each group (one and
two patients, respectively). Parental samples of patient 8
with matUPD7 were also tested, to compare expression
levels between a child and the parents (ﬁg. 2B). The ex-
pression levels of the parental samples (8.15 [SEM 2.06])
corresponded with the other controls and were, thus, sig-
niﬁcantly higher than those of their child (0.05 [SEM
0.01]; ). These results suggest that the multitran-Pp .029
script FOXP2 locus is differentially regulated in a parent-
of-origin–speciﬁc manner. The lack of coding variants in
FOXP2 makes it difﬁcult to study parent-of-origin–speciﬁc
expression in individuals who are diploid for the locus.
On the basis of our data, it is possible, for the ﬁrst time,
to attribute the speech and language phenotype of the
patients with matUPD7—observed primarily in the pa-
tients with SRS (with matUPD7)—to absence of paternal
FOXP2. This ﬁnding, coupled with the observation that
all other non-DVD features of SRS are present in patient
15, who has partial matUPD7q31-qter, indicates that two
or more genes likely contribute to the chromosome 7 form
of this disorder. Moreover, none of the patients with the
FOXP2 deletion exhibited typical SRS features. In our in-
terpretation, FOXP2 accounts for the DVD, and one or
more other genes mapping to the 7q32-qter cause the in-
trauterine and postnatal growth retardation symptoms.
Whereas there is a cluster of imprinted genes localized to
7q32 (ﬁg. 1A), the causative SRS gene(s) on chromosome
7 remains to be identiﬁed.
Interestingly, four patients with FOXP2 deletion (3, 4,
13, and 18) were also given diagnoses of ASD, providing
a clinically homogeneous group distinguishable from pa-
tients with other forms of ASD. Since speech delay is a
component of ASD, it has been speculated that FOXP2
itself may be implicated in autism.21,22 The same general
7q31 region has been shown, by linkage analysis of sib-
pair families23,24 and chromosome rearrangement stud-
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Figure 2. Results of qPCR used to estimate FOXP2 expression in
cell lines from patients with deletions, a translocation, matUPD7,
and patUPD7 and from controls. GAPDH was used as reference.
Analysis was performed with a subset of samples for which RNA
was available. Taqman qPCR of FOXP2 exons 13–14 was run on (A)
six patients with deletions (patients 1–4 and the two nonverbal
patients, 18 and 21), one patient with a translocation (patient
6), six patients with matUPD7 (patients 7–12), two patients with
patUPD7 (patients 16 and 17), seven control samples, and (B)
patient 8 with matUPD7 and his parents. There was a signiﬁcant
difference between the groups (ANOVA ). There was aPp .0003
statistically signiﬁcant difference between the patients with
matUPD7 and controls and between patients with deletions and
controls (ANOVA and Dunnett’s post hoc test). The expression for
patient 8 was also signiﬁcantly lower than in his parents (two-
tailed t test ). Statistical analysis was not performed forPp .03
the patients with the translocation and patUPD7 because of small
sample size. All samples were run in triplicate, and the experiment
was repeated twice, with consistent results. Bars indicate SEM. For
qPCR, 2 mg of total RNA was reversely transcribed in a 100-ml
reaction with random hexamers, with the use of Taqman Reverse
Transcription Reagents kit, and real-time PCR was performed using
an ABI7700 sequence-detection system. PCR was performed in 25-
ml reactions with 45 cycles of ampliﬁcation. Each plate contained
a water control, a calibrator sample (control 1 cDNA), and serially
diluted concentrations of control 3 cDNA (range 62.5–0.5 ng),
from which a standard curve was generated for transcript
quantiﬁcation.
ies,25,26 to harbor a putative autism susceptibility locus.
There are also reports describing an increased transmission
of paternal alleles for markers associated with autism, sug-
gesting the presence of a maternally imprinted gene at
7q31.23,27 Our results, however, do not provide any direct
support that FOXP2 is etiologic in idiopathic ASD, which
is consistent with other ﬁndings.21,22,28 Instead, it is pos-
sible that those rare patients with ASD and demonstrating
DVD will have genetic lesions affecting FOXP2 in com-
bination with variants in other susceptibility genes, some
of which might also reside on chromosome 7.
In any scenario, our data emphasize the need to ex-
amine the entire 1600 kb FOXP2 locus, its many tran-
scripts including untranslated exons, and putative sur-
rounding regulatory regions, when the gene or gene ex-
pression is being tested for involvement in disease. Since
some isoforms of the gene (e.g., FOXP2-S5) may not in-
clude the forkhead domain (and may not be transcription
factors) and/or potentially othermotifs, accurate genotype
and phenotype interpretations will require substantially
greater sample size. This is further highlighted by the pa-
tient with a translocation breakpoint between exons s1
and s2. One or both of these untranslated exons have not
been included in most mutation screens of FOXP2 in co-
horts with DVD and autism.7,21,22
There are differentmodels that can reconcile our current
observations with data published elsewhere. We hypoth-
esize that, just as has been shown with many of the FOX
genes and proteins, proper dosage of FOXP2 at precise
times and locations (at the cellular and tissue levels) is
required for normal development.29 On the basis of our
data, the majority of FOXP2 transcripts are of paternal
origin, so individuals with chromosome deletions inher-
ited from the father or with matUPD7 or other function-
ally equivalent mutations would display a more severe
phenotype. There is no phenotypic information available
that allows comparison of patients carrying mutations of
maternal and paternal origin, respectively, in the KE fam-
ily. Clearly, mutations in the maternal copy of FOXP2 is
sufﬁcient to cause a DVD phenotype, as reported in both
the KE family3 and a multiplex family in which both the
mother and her two children carry a nonsense mutation
in exon 7, which segregates with the DVD phenotype.7 It
is possible that these mutations could express themselves
at the level of the protein in a dominant-negativemanner
consistent with FOXP2 requiring dimerization for bind-
ing30 and for other functions attributed to different iso-
forms of the gene. However, our interpretation is that the
difference between maternal and paternal mutations/de-
letions will be manifested at the level of phenotypic
severity.
Variability in expression levels between maternal and
paternal chromosomes could reﬂect either imprinting of
a chromosome 7 gene involved in regulation of FOXP2
transcription or imprinting affecting one ormore isoforms
of FOXP2. The difference in severity of DVD seen among
the different types of aberrations—with an increase in se-
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verity for UPD, mutation, and deletion—is similar to the
ﬁndings for the imprinted Angelman Syndrome/Prader-
Willi Syndrome region on chromosome 15.31 However, no
direct evidence of imprinting of FOXP2 itself has yet been
found. The lack of coding variants in FOXP2 makes it dif-
ﬁcult to study parent-of-origin–speciﬁc expression in in-
dividuals who are diploid for the locus. We have, there-
fore, searched for tissue-speciﬁc imprinting in mouse but
have not yet observed it (unpublished data). An alterna-
tive explanation of our data is that (i) the preponderance
of paternal deletionsmerely reﬂects a highermutation rate
occurring during spermatogenesis compared with oogen-
esis32 and/or that (ii) deletion of the maternally inherited
allele is selected against during development. The descrip-
tion of the two patients with patUPD7 in our study and
of one other in the literature33 argues against the latter
scenario. It could also be possible that there is amaternally
imprinted gene near FOXP2 within the minimal interval
deﬁned by patients 4 and 6 (deﬁning a centromeric
boundary) and patient 14 (deﬁning a telomeric boundary)
(ﬁg. 1), but, so far, no such transcript has been found.
In summary, our ﬁndings suggest that DVD presenting
either in isolation, as part of a syndrome such as SRS, or
in a more complex setting like ASD can be attributable to
lesions or imbalances affecting the FOXP2 locus. Whereas
substantial attention has been focused on the nature of
conservation of the protein through evolution and on hu-
man-speciﬁc variants,34 differential allelic expression of
FOXP2 and, possibly, maternal imprinting may be equally
important in human development and disease.
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